Targeted Cancer Therapies Archives - NFCR

Targeted Cancer Therapies

Brian Leyland-Jones: Now Is the Time!

“This is the transformative time in oncology,” heralds Brian Leyland-Jones, M.B., B.S., Ph.D., and there is no spin doctoring in the statement by the member of the National Foundation for Cancer Research’s scientific advisory board. From genomics to targeted therapies to vaccinations, the last 40 years has seen more strides…...

Read more

Targeted Lung Cancer Therapy

A Match Made Possible A discovery by a team led by Massachusetts General Hospital’s Daniel Haber, M.D., Ph.D., a physician-scientist supported by the National Foundation for Cancer Research since 2003, now represents a source of hope for many patients with metastatic lung cancer. He and his colleagues correctly linked very…...

Read more

New Type of Lung Cancer Identified

A research team at Cold Spring Harbor Laboratory discovered a new kind of small-cell lung cancer (SCLC). While the general public may not consider this particularly good news, the identification paves the way for developing more specific and personalized medicine approaches to target this previously unnoticed form of the disease....

Read more

Artemisinin Therapies: Connecting the Dots

You wouldn’t think it, but the science cannot be denied: One of the newest and most promising drug candidates for cancer was actually developed all the way back in 1972. For malaria. “There were some hints in the literature, but we were totally ignorant,” admits Curt Civin, M.D., whose work…...

Read more

Pediatric Cancer Drug Has 93 Percent Effectiveness

A new cancer drug, larotrectinib, has in a very early clinical trial been shown to have a 93% (14/15) effectiveness rate for pediatric cancers; that is to say, for not just one cancer, but many. Hailed by the U.S. Food and Drug Administration as a “breakthrough therapy,” larotrectinib targets a…...

Read more